Urogen Pharma Q3 2025 Earnings Report

Urogen Pharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.70
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Urogen Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $34.09 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Urogen Pharma Announcement Details

• Quarter: Q3 2025
• Date: 11/5/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 5, 2025
• Conference Call Time: 10:00AM ET

Urogen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer. Jelmyto represents the first FDA-approved therapy for this indication, offering a minimally invasive, kidney-sparing alternative to surgery. Beyond Jelmyto, UroGen’s pipeline includes UGN-102, an investigational mitomycin solution under study for interstitial cystitis/bladder pain syndrome, and earlier-stage programs targeting other urologic and ophthalmic conditions leveraging the RTGel platform.

UroGen markets its products primarily in the United States and is pursuing regulatory submissions in Europe and other global regions. The company’s management team is led by Co-Founder and Chief Executive Officer Tomer Kariv, supported by Chief Operating Officer Vas Narasimhan and Chief Medical Officer Philip Isaacs, among others. UroGen collaborates with key opinion leaders in urology to advance its clinical programs and expand patient access to novel in-office therapies.